



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

06 Jul 2020 (#32)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notice

- [NOT-OD-20-125](#): Reminder of Upcoming FORMS-F and Inclusion Across the Lifespan Requirements for NIH Applicants
- [Grant recipients are now required to submit participant-level data on gender, race, ethnicity, and age at enrollment in progress reports](#), which is consistent with the Inclusion Across the Lifespan policy and new application forms F. Refer to [NOT-OD-20-125](#) for a complete list of significant form changes in Forms F.
- [Upcoming Mandatory Submission of the Federal Financial Report \(FFR\)](#) in the Payment Management System Beginning January 1, 2021
- [Is your application responsive to the goals of the selected funding opportunity?](#) Announcements with set-aside funds may now include criteria that would make an application non-responsive i.e., outside the scope of the PAR or PAS. Read the full description in section 1 carefully. Applications that are deemed non-responsive will be withdrawn from review. Applicants are strongly encouraged to contact the applicable Program Official listed on the FOA.
- [NIH Implementation of OMB Memorandum M-20-26](#) “Extension of Administrative Relief for Recipients and Applicants of Federal Financial Assistance Directly Impacted by the Novel Coronavirus (COVID-19) due to Loss of Operations”
- [What Is a “Rolling” Submission Date?](#) It is more common with “emergency” or “urgent” funding opportunities meant to get funding to the community as quickly as possible to address a critical need.
- [NOT-OD-20-132](#): Updated AVMA Guidelines for the Euthanasia of Animals: 2020 Edition
- [NOT-OD-20-139](#): Findings of research misconduct
- [NOT-HD-20-019: Notice of Special Interest: Research to Advance the Understanding and Management of the Multiple Organ Dysfunction Syndrome in Children \(R01, R21\)](#). The purpose of this Notice of Scientific Interest (NOSI) is to continue a program of research to advance the understanding, prevention and treatment of pediatric multiple organ dysfunction syndrome (MODS). This Notice applies to due dates on or after October 5, 2020 and subsequent receipt dates through September 8, 2022. Submit applications for this initiative using one of the following FOAs or any reissues of these announcements through the expiration date of this Notice.
[PA-20-185](#): Research Project Grant (Parent R01 Clinical Trial Not Allowed)
[PA-18-480](#): NICHD Research Project Grant (R01 Clinical Trial Required)
[PA-18-482](#): NICHD Exploratory/Developmental Research Grant (R21 - Clinical Trial Optional)
- [NOT-HL-20-787: Notice of Special Interest \(NOSI\): Understanding Sudden Death in the Young Through Research](#). This Notice of Special Interest (NOSI) highlights interest in receiving grant applications focused on mechanistic, genetic, and other studies to evaluate causes and consequences of and risk factors for sudden death in the young. Studies are required to use data and DNA samples, and associated sequence data from the NIH/CDC

Sudden Death in the Young (SDY) Case Registry as foundations for their research. Results of such studies are expected to be disseminated widely and to provide an evidence base to advance discussions about screening and prevention of SDY. This notice applies to due dates on or after October 5, 2020 and subsequent receipt dates through January 8, 2023. Submit applications for this initiative using the following funding opportunity announcement (FOA) or any reissues of this announcement through the expiration date of this notice [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed).

1. BRAIN Initiative: Proof of Concept Development of Early Stage Next Generation Human Brain Imaging (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-EB-20-001](#)

Type: R01

Application Due Date: 3 September 2020; 3 September 2021. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This funding opportunity announcement (FOA), in support of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, aims to support early stage development of entirely new noninvasive imaging methods or unusually bold approaches for existing noninvasive imaging methods that will lead to transformative advances in our understanding of the function and connectivity of the human brain. The FOA solicits small-scale projects to prove exceptionally innovative, original and/or unconventional concepts.

Budget: Issuing IC and partner components intend to commit an estimated total of \$ 4M to fund 6-12 awards. Application budgets are limited to \$300,000 in direct costs in any project year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

2. BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-EB-20-002](#)

Type: R01

Application Due Date: 14 September 14 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This FOA solicits the development of theories, computational models, and analytical tools to derive understanding of brain function from complex neuroscience data. Proposed projects could develop tools to integrate existing theories or formulate new theories; conceptual frameworks to organize or fuse data to infer general principles of brain function; multiscale/multiphysics models to generate new testable hypotheses to design/drive future experiments; new analytical methods to either support or refute a stated hypothesis about brain function. It is expected that the tools developed under this FOA will be made widely available to the neuroscience research community for their use and modification. Investigative studies should be limited to model parameter estimation and/or validity testing of the tools being developed.

Budget: Then NIH BRAIN initiative anticipates providing \$6M per year to fund up to 15 awards each year. Application budgets not limited, but are expected to range between \$150,000 to \$250,000 direct costs per year. Investigators are expected to request a budget that is required to accomplish the proposed work. Awards are for three years of support.

3. Renewal-Harmonization of Technical Requirements for Pharmaceuticals for Human Use (U01) Clinical Trials Not Allowed

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-FD-21-002](#)

Type: U01

Application Due Date: 13 October 2020, by 11:59 PM Eastern Time.

Funding Opportunity Announcement: The Food and Drug Administration announces its intention to consider and accept a renewal application for award to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The purpose of this program is to provide support in convening regional pharmaceutical regulatory authorities and pharmaceutical industry associations representing regions and jurisdictions from around the world to achieve greater harmonization of scientific and technical standards for pharmaceuticals. This is to ensure that safe, effective, and high-quality medicines are developed and registered in the most resource-efficient manner, to be available to patients globally. The outcome of this effort will be a series of internationally recognized guidelines for pharmaceutical product registration, adopted by regulators in regions around the world.

Budget: FDA/CDER intends to fund up to \$500,000, for fiscal year 2021 in support of this grant program. It is anticipated that up to one (1) award will be made, not to exceed \$500,000 in total costs (direct plus indirect), per award. The maximum project period is five (5) years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105